IL-17A Damages the Blood-Retinal Barrier through Activating the Janus Kinase 1 Pathway.

Biomedicines · 2021 · PMC8301352 · PMID 34356895

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Tofacitinib Citrate treatment slightly reduced IL-17A-mediated retinal pJAK1 expression; however, the reduction did not reach statistical significance ( Figure 5 C), which may be related to the large variation and insufficient sample size. 3.6.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.